​

89bio (ETNB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ETNB Stock Forecast

89bio (ETNB) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $14.50, with a high of $14.50 and a low of $14.50. This represents a -2.23% decline from the last price of $14.83.

$7 $8 $9 $10 $11 $12 $13 $14 $15 High: $14.5 Avg: $14.5 Low: $14.5 Last Closed Price: $14.83

ETNB Stock Rating

89bio stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (60.00%), 6 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 6 9 Strong Sell Sell Hold Buy Strong Buy

ETNB Price Target Upside V Benchmarks

TypeNameUpside
Stock89bio-2.23%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$14.50$14.50
Last Closing Price$14.83$14.83$14.83
Upside/Downside--2.23%-2.23%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-44--8
Sep, 25-82--10
Aug, 25182--11
Jul, 25182--11
Jun, 25182--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 19, 2025H.C. Wainwright$14.50$14.96-3.07%-2.23%
Aug 06, 2024Brian AbrahamsRBC Capital$12.00$8.0349.44%-19.08%
Jun 07, 2024Eliana MerleUBS$25.00$8.10208.64%68.58%
May 10, 2024Ed ArceH.C. Wainwright$29.00$9.00222.22%95.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 19, 2025Raymond JamesStrong BuyMarket Performdowngrade
Sep 19, 2025H.C. WainwrightBuyNeutraldowngrade
Sep 18, 2025Wolfe ResearchOutperformPeer Performdowngrade
Feb 03, 2025Wolfe ResearchOutperforminitialise
Jan 31, 2025UBSBuyBuyhold
Aug 06, 2024Raymond JamesStrong BuyStrong Buyhold
Aug 06, 2024RBC CapitalSector PerformSector Performhold
Jun 07, 2024UBSBuyBuyhold
May 14, 2024Evercore ISIOutperformOutperformhold
May 10, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.93$-2.00$-3.51----
Avg Forecast$-3.04$-2.03$-3.27$-2.74$-2.80$-1.87$-0.08
High Forecast$-3.04$-1.82$-2.98$-2.40$-2.52$-0.31$-0.08
Low Forecast$-3.04$-2.50$-3.49$-2.94$-3.25$-2.79$-0.08
Surprise %-3.62%-1.48%7.34%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$1.25M$267.86K$1.25M$2.92M$25.31M$175.88M$439.66M
High Forecast$1.25M$267.86K$1.25M$2.92M$25.31M$175.88M$439.66M
Low Forecast$1.25M$267.86K$1.25M$2.92M$25.31M$175.88M$439.66M
Surprise %-------

Net Income Forecast

$-400M $-320M $-240M $-160M $-80M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-102.03M$-142.19M$-367.08M----
Avg Forecast$-216.42M$-153.76M$-230.25M$-189.77M$-205.47M$-110.20M$-5.41M
High Forecast$-216.42M$-129.30M$-211.77M$-170.55M$-179.60M$-21.81M$-5.41M
Low Forecast$-216.42M$-178.22M$-248.72M$-208.99M$-231.34M$-198.58M$-5.41M
Surprise %-52.86%-7.53%59.43%----

ETNB Forecast FAQ

Is 89bio stock a buy?

89bio stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that 89bio is a favorable investment for most analysts.

What is 89bio's price target?

89bio's price target, set by 15 Wall Street analysts, averages $14.5 over the next 12 months. The price target range spans from $14.5 at the low end to $14.5 at the high end, suggesting a potential -2.23% change from the previous closing price of $14.83.

How does 89bio stock forecast compare to its benchmarks?

89bio's stock forecast shows a -2.23% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for 89bio over the past three months?

  • October 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 9.09% Strong Buy, 72.73% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is 89bio’s EPS forecast?

89bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.74, marking a -21.94% decrease from the reported $-3.51 in 2024. Estimates for the following years are $-2.8 in 2026, $-1.87 in 2027, and $-0.08 in 2028.

What is 89bio’s revenue forecast?

89bio's average annual revenue forecast for its fiscal year ending in December 2025 is $2.92M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25.31M, followed by $175.88M for 2027, and $439.66M for 2028.

What is 89bio’s net income forecast?

89bio's net income forecast for the fiscal year ending in December 2025 stands at $-190M, representing a -48.30% decrease from the reported $-367M in 2024. Projections indicate $-205M in 2026, $-110M in 2027, and $-5.409M in 2028.